Last reviewed 2026-05-14 · How we verify

efavirenz + emtricitabina + tenofovir

efavirenz + emtricitabina + tenofovir is a Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) Small molecule drug developed by Hospital Universitari Vall d'Hebron Research Institute. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy. Also known as: atripla.

This combination of three antiretroviral drugs suppresses HIV replication by inhibiting reverse transcriptase and blocking viral integration into host cells.

This combination of three antiretroviral drugs suppresses HIV replication by inhibiting reverse transcriptase and blocking viral integration into host cells. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy.

At a glance

Mechanism of action

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the enzyme HIV uses to convert its RNA genome into DNA. Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) that act as chain terminators during viral DNA synthesis. Together, they provide potent suppression of HIV viral load when used as combination antiretroviral therapy.

Approved indications

• HIV-1 infection in treatment-naïve and treatment-experienced patients
• HIV-1 infection as part of combination antiretroviral therapy

Common side effects

• Dizziness and CNS effects
• Rash
• Nausea
• Headache
• Abnormal dreams/nightmares
• Renal dysfunction (tenofovir-related)
• Bone density loss

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
• Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection (PHASE1)
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
• Research on the Psychological Status of Patients With HIV-1 Infection
• Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• efavirenz + emtricitabina + tenofovir CI brief — competitive landscape report
• efavirenz + emtricitabina + tenofovir updates RSS · CI watch RSS
• Hospital Universitari Vall d'Hebron Research Institute portfolio CI

Frequently asked questions about efavirenz + emtricitabina + tenofovir

Related

• Drug class: All Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) drugs
• Target: All drugs targeting HIV reverse transcriptase, HIV integrase
• Manufacturer: Hospital Universitari Vall d'Hebron Research Institute — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Virology
• Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
• Indication: Drugs for HIV-1 infection as part of combination antiretroviral therapy
• Also known as: atripla
• Compare: efavirenz + emtricitabina + tenofovir vs similar drugs
• Pricing: efavirenz + emtricitabina + tenofovir cost, discount & access